Talquetamab, a T-Cell–Redirecting GPRC5D Bispecific Antibody for Multiple Myeloma
New England Journal of Medicine2022Vol. 387(24), pp. 2232–2244
Citations Over TimeTop 1% of 2022 papers
Ajai Chari, Monique C. Minnema, Jesús G. Berdeja, Albert Oriol, Niels W.C.J. van de Donk, Paula Rodríguez‐Otero, Elham Askari, María‐Victoria Mateos, Luciano J. Costa, Jo Caers, Raluca Verona, Suzette Girgis, Shiyi Yang, Rachel B. Goldsmith, Xiang Yao, Kodandaram Pillarisetti, Brandi Hilder, Jeffery S. Russell, Jenna D. Goldberg, Amrita Krishnan
Abstract
Cytokine release syndrome, skin-related events, and dysgeusia were common with talquetamab treatment but were primarily low-grade. Talquetamab induced a substantial response among patients with heavily pretreated relapsed or refractory multiple myeloma. (Funded by Janssen Research and Development; MonumenTAL-1 ClinicalTrials.gov number, NCT03399799.).
Related Papers
- → Preliminary estimation of the prevalence of chemotherapy-induced dysgeusia in Japanese patients with cancer(2013)47 cited
- → Evaluation of Chemotherapy-induced Dysgeusia in Patients With Gastrointestinal Cancer: A Pilot Study(2023)7 cited
- → Incidence and Treatment of Dysgeusia in Patients with Glossodynia(2002)25 cited
- → Dysgeusia and COVID-19: the Importance of the Dentist in the Diagnostic(2021)2 cited
- → Dysgeusia(2022)